retatrutide d Acute and chronic effects of retatrutide, semaglutide and long‐acting CagriSema vs Tirzepatide vs Retatrutide:

Regardless of the mechanism, the outcome can feel similar: progress slows or stops

Systemically, because it involves copper, there is a theoretical risk of copper overload with prolonged, high-dose use without proper cycling

Liraglutide shares 97% sequence homology with human GLP-1 and can bind to and activate GLP-1R.78 The elimination half-life of liraglutide is 13 h, and only one injection per day is required.62 Lixisenatide Lixisenatide was developed by Sanofi to treat T2DM.64,93 Structurally, lixisenatide is based on the exenatide structure but lacks proline at position 38, and six lysines are linked after serine at position 39.94 The six lysine residues increase the rigidity of the molecules structure, thus allowing its drug properties to be improved.78 These changes stabilize its structure, prevent protein degradation of the molecule in the circulation, and increase the circulation time enough to ensure once-daily injection (compared with exenatide, which is injected two or three times daily)

Its not guaranteed to succeed, but the early data is compelling